- Home
- PBM vs KZIA Comparison
PBM vs KZIA Comparison
Compare PBM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBM
- KZIA
- Stock Information
- Founded
- PBM 1994
- KZIA 1994
- Country
- PBM Canada
- KZIA Australia
- Employees
- PBM N/A
- KZIA N/A
- Industry
- PBM
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PBM
- KZIA Health Care
- Exchange
- PBM NYSE
- KZIA Nasdaq
- Market Cap
- PBM 7.5M
- KZIA 7.8M
- IPO Year
- PBM N/A
- KZIA 1999
- Fundamental
- Price
- PBM $1.79
- KZIA $1.42
- Analyst Decision
- PBM
- KZIA Strong Buy
- Analyst Count
- PBM 0
- KZIA 1
- Target Price
- PBM N/A
- KZIA $20.00
- AVG Volume (30 Days)
- PBM 5.4M
- KZIA 116.4K
- Earning Date
- PBM 02-02-2025
- KZIA 11-15-2024
- Dividend Yield
- PBM N/A
- KZIA N/A
- EPS Growth
- PBM N/A
- KZIA N/A
- EPS
- PBM N/A
- KZIA N/A
- Revenue
- PBM N/A
- KZIA $1,655,324.00
- Revenue This Year
- PBM N/A
- KZIA $806.89
- Revenue Next Year
- PBM N/A
- KZIA N/A
- P/E Ratio
- PBM N/A
- KZIA N/A
- Revenue Growth
- PBM N/A
- KZIA 248000.00
- 52 Week Low
- PBM $1.51
- KZIA $1.39
- 52 Week High
- PBM $593.25
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PBM 39.22
- KZIA 20.74
- Support Level
- PBM $1.61
- KZIA $1.42
- Resistance Level
- PBM $2.25
- KZIA $1.89
- Average True Range (ATR)
- PBM 0.22
- KZIA 0.24
- MACD
- PBM 0.06
- KZIA 0.02
- Stochastic Oscillator
- PBM 23.38
- KZIA 1.40
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.